PMID- 30320629
OWN - NLM
STAT- In-Process
LR  - 20190219
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 29
IP  - 1
DP  - 2019 Feb
TI  - A plasma microRNA biomarker of melanoma as a personalised assessment of treatment
      response.
PG  - 19-22
LID - 10.1097/CMR.0000000000000492 [doi]
AB  - New tools for monitoring response to primary melanoma treatment are needed to
      reduce recurrence rates and patient anxiety. A previously developed plasma-based 
      microRNA signature (MEL38) was measured in four melanoma patient samples obtained
      before and 12-14 days after treatment (i.e. surgical excision), as well as in two
      nonmelanoma controls. The value of the MEL38 score and selected individual genes 
      were compared between the time points. The MEL38 scores of the four patients with
      melanoma became more 'normal like' after tumour excision, with a statistically
      significant 15% mean reduction. MicroRNAs involved in tumour suppression were
      upregulated in the postexcision samples and those involved in facilitating
      treatment resistance and tumour invasion were downregulated. Based on these
      limited preliminary data, the MEL38 signature may have clinical utility in
      assessing an individual patient's response to the most common form of melanoma
      treatment. Additional studies are needed on larger, clinically diverse patient
      cohorts, sampled over longer periods of time.
FAU - van Laar, Ryan K
AU  - van Laar RK
AD  - Geneseq Biosciences, Balaclava, Victoria, Australia.
FAU - Lincoln, Mitchel T
AU  - Lincoln MT
FAU - van Laar, Barton J
AU  - van Laar BJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
EDAT- 2018/10/16 06:00
MHDA- 2018/10/16 06:00
CRDT- 2018/10/16 06:00
PHST- 2018/10/16 06:00 [pubmed]
PHST- 2018/10/16 06:00 [medline]
PHST- 2018/10/16 06:00 [entrez]
AID - 10.1097/CMR.0000000000000492 [doi]
PST - ppublish
SO  - Melanoma Res. 2019 Feb;29(1):19-22. doi: 10.1097/CMR.0000000000000492.